New CMS waiver policy aims to expand Medicaid treatments for SUDs

Nov 01, 2017 - 12:08 PM

The Centers for Medicare & Medicaid Services today announced a new Section 1115 waiver policy that allows states to design demonstration projects that increase access to treatment for opioid use disorders and other substance use disorders. CMS’s new demonstration policy would allow state Medicaid programs to reimburse for substance abuse treatment provided at inpatient facilities with more than 16 beds otherwise prohibited by the current Institutions for Mental Diseases exclusion. While the new policy will provide states with an expedited review process, it does require that states submit a detailed implementation plan that articulates how they will meet the new policy’s specific goals and milestones to improve OUD and SUD treatment and reduce opioid related deaths. In addition to the implementation plan, states also must comply with periodic reporting and evaluations. CMS also announced approval of New Jersey and Utah’s 1115 demonstration waivers under the new policy.

Related News Articles

Headline
FDA issues RFI on in-home opioid disposal products
The Food and Drug Administration March 5 issued a request for information seeking public comments on potential new standards for in-home opioid disposal…
Headline
FDA issues guidance to expand non-opioid treatments for chronic pain
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
Study finds less than 40% of Medicare beneficiaries with OUD receive standard care
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
FDA announces labeling changes to opioid pain medications 
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
Overdose deaths dropped an estimated 27% in 2024
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…
Headline
FDA approves first-in-class non-opioid painkiller 
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…